RxDoctor Payments Data

Moris Angulo

Pediatric Endocrinology · Mineola, NYNPI 1477573269

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $43,669 of the $72,758 with a category attached, or 60.0%. Novo Nordisk accounts for 79.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $33,832 and has fallen 98.6% since, to $471 in 2025. Among pediatric endocrinology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$72,758in general payments, 2019–2025

Across 128 payments — averaging $568.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$58K
  • Ascendis Pharma Endocrinology Inc$13K
  • Biomarin Pharmaceutical Inc.$457
  • Soleno Therapeutics, Inc.$202
  • AbbVie$155
  • Neurocrine Biosciences, Inc.$150
  • plus $546 from 15 others
$306,355in research payments, 2019–2025

Across 42 payments — averaging $7294.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Soleno Therapeutics, Inc.$222K
  • Novo Nordisk AS$84K

What the payments were for

  • Consulting fees$16,70223%
  • Speaking & faculty fees$43,66960%
  • Travel & lodging$8,61012%
  • Food & beverage$3,0034%
  • Education$7741%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,758 in reported general payments places this provider in the 95th percentile of 138 pediatric endocrinology providers in New York.

See all pediatric endocrinology providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levothyroxine Sodium28$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$48728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pediatric endocrinology providers in New York.

Other pediatric endocrinology in Mineola

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →